Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Weight Watchers went bankrupt in May, but now it promises it's trimmed the fat off its books and is ready to rejoin the ...

Leerink Partners trimmed its Q2 2025 earnings estimate for Eli Lilly to $5.40 per share, down from $5.54. Several firms ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of Lilly stock.

Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at boosting domestic drug ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...

Looking at drug momentum, supply stability, and DTC growth, here’s what we think of Eli Lilly’s stock.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Drugmaker Eli Lilly (LLY 0.40%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the ...